Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this prospective national multicenter randomized study is to compare, during an ERCP for VBP stenosis, the sensitivity of two biliary brushes: the INFINITY® vs the RX Cytology Brush® The main objective is the comparison of the rates of positive diagnosis of biliary brushing in cases of adenocarcinoma stenosis The total number of subjects required: 50 (25 patients per group) Duration of the inclusion period: 2 years Duration of participation for each subject: from 7 days to 12 months (in case of negative initial withdrawal) Total duration of the study: 3 years
The aim of this study is to compare, during an ERCP for VBP stenosis, the sensitivity of two biliary brushes: the INFINITY® vs the RX Cytology Brush®
OBJECTIVES
Main objective: Comparison of the rates of positive diagnosis of biliary brushing in cases of adenocarcinoma stenosis
Secondary objective (s):
This study concerns adult subjects with stenosis of the main bile duct (common bile duct or common hepatic duct).
ENDOSCOPIC PROCEDURE
Deep catheterization of the biliary duct (whatever the access technique: by the papilla or by precut) and cross stenosis by the guide wire, then biliary dilation (6 to 8mm)
Randomization if the inclusion criteria are met
Biliary brushing successively with the 2 brushes in the order designated by randomization:
In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)
All possible sampling methods will also be taken to obtain the anatomopathological diagnosis: intra-biliary biopsies with adult or pediatric forceps, wire-guided or not, biopsy samples guided by choledochoscopy, puncture under endo-ultrasonography, bile aspiration after release of the biliary stent, according to the physician's habits.
EFFECTIVE The total number of subjects required: 50 (25 patients per group) Duration of the inclusion period: 2 years Duration of participation for each subject: from 7 days to 12 months (in case of negative initial withdrawal) Total duration of the study: 3 years
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A: RX Cytology brush, Boston Scientific FIRST | Active Comparator | A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy |
|
| Group B: Infinity®, US Endoscopy FIRST | Active Comparator | A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biliary brushing with the RX Cytology brush, Boston Scientific | Device | Biliary brushing during ERCP:
|
| Measure | Description | Time Frame |
|---|---|---|
| Sensibility for adenocarcinoma | Rate of positive diagnosis of biliary brushing in case of cholangiocarcinoma stenosis | 8 days to 1 year (if negative) |
| Measure | Description | Time Frame |
|---|---|---|
| Sample abundance | Quantification of the cellular material obtained (acellular, weak, or abundant), presence of cellular cupboards unhooked by the brush or average number of cells per field | 8 days |
| False negative |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique Paris Bercy | Charenton-le-Pont | F-94220 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36849106 | Derived | Karsenti D, Privat J, Charissoux A, Perrot B, Leblanc S, Chaput U, Boytchev I, Levy J, Schaefer M, Bourgaux JF, Valats JC, Coron E, Moreno-Garcia M, Vanbiervliet G, Rahmi G, Robles EP, Wallenhorst T. Multicenter randomized trial comparing diagnostic sensitivity and cellular abundance with aggressive versus standard biliary brushing for bile duct stenosis without mass syndrome. Endoscopy. 2023 Sep;55(9):796-803. doi: 10.1055/a-2041-7687. Epub 2023 Feb 27. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
National prospective multicenter RCT
Not provided
Not provided
Not provided
Not provided
|
| Biliary brushing with the Infinity® brush, US Endoscopy | Device | Biliary brushing during ERCP:
|
|
Negative brushing for a final diagnosis of cholangiocarcinoma
| 1 year |
| Predictive Negative Value | probability that patients with a negative brushing truly don't have cholangiocarcinoma | 1 year |
| Feasibility of the 2 brushes: Analog visual scale | Analog visual scale: Feasibility scale (0 to 10, 0 for Extremely difficult to perform and 10 for very easy to perform) | 1 day |
| Feasibility of the intra-biliary biopsies: Analog visual scale | Analog visual scale: Feasibility scale (0 to 10, 0 for Extremely difficult to perform and 10 for very easy to perform) | 1 day |
| Feasibility of bile aspiration: Analog visual scale | Analog visual scale: Feasibility scale (0 to 10, 0 for Extremely difficult to perform and 10 for very easy to perform) | 1 day |
| Feasibility of stenosis puncture under ultrasonography: Analog visual scale | Analog visual scale: Feasibility scale (0 to 10, 0 for Extremely difficult to perform and 10 for very easy to perform) | 1 day |
| ID | Term |
|---|---|
| D041781 | Jaundice, Obstructive |
| ID | Term |
|---|---|
| D007565 | Jaundice |
| D006932 | Hyperbilirubinemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided